Vyvanse Approved for Additional Dosage Strengths

Shire plc, the pharmaceutical company which produces the ADHD medication Vyvanse, announced that it has received approval from the FDA to release the drug in three additional dosage strengths. The existing doses of 30 mg, 50 mg and 70 mg will be supplemented with 20 mg, 40 mg 60 mg doses.

"Dose titration, the process of incrementally increasing or decreasing the dose of a medication, is a widely used method in clinical practice to help achieve optimal efficacy and tolerability for each patient. The option of having dosage strengths with smaller increments allows for a more gradual titration of medication and may help the physician tailor the treatment for each individual patient."

More than 500,000 prescriptions for Vyvanse were dispensed in the first six month the drug was available. The CEO of Shire believes it's an indication that doctors view Vyvanse as an effective treatment option.